Home>>BNTA

BNTA Sale

目录号 : GC60650

BNTA是一种有效的细胞外基质(ECM)调节剂,通过激活超氧化物歧化酶3(SOD3)促进软骨细胞上软骨结构分子的合成。BNTA促进软骨细胞外基质的生成并抑制骨关节炎的发展。BNTA可用于骨关节炎的研究。

BNTA Chemical Structure

Cas No.:685119-25-9

规格 价格 库存 购买数量
5mg
¥2,700.00
现货
10mg
¥4,500.00
现货
25mg
¥8,550.00
现货
50mg
¥13,950.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

BNTA, a potent extracellular matrix (ECM) modulator, facilitates cartilage structural molecule synthesis on chondrocytes by activating superoxide dismutase 3 (SOD3). BNTA promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. BNTA has the potential for the research of osteoarthritis[1].

BNTA (0.01-10 μM; 1-7 d) does not decrease cell viability of human osteoarthritis chondrocytes and rat primary chondrocytes[1].BNTA (0.1 μM; 2 d) increases SOX9 protein markedly[1].BNTA (0.1 μM; 2 d) remarkably increases the COL2A1 and SOX9 protein levels in IL1β-induced rat OA chondrocytes[1].BNTA (10 μM; 5 d) increases proteoglycan staining in ATDC5 cells[1].BNTA (0.01-10 μM; 6 h) upregulates the expression levels of ECM-related genes COL2A1, ACAN, proteoglycan 4 (PRG4), and SRY-box 9 (SOX9) in human OA chondrocytes[1].BNTA (0.01-10 μM; 6 h) increases Col2a1, Acan, Prg4, and Sox9 mRNA levels, with maximum effects around 0.1 μM in IL1β-induced rat OA chondrocytes[1].BNTA (0.01-1 μM; 2 or 3 w) enhances anabolism and inhibited inflammatory response in osteoarthritis cartilage explants[1]. Cell Viability Assay[1] Cell Line: Human OA chondrocytes

BNTA (0.015-1.5 mg/kg; intra-articular injection; twice a week for 4 and 8 weeks) could attenuate OA progression developed after anterior cruciate ligament transection (ACLT) in rats[1]. Animal Model: Male SD rats weighing 80 g are induced by ACLT[1]

[1]. Shi Y, et, al. A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development. Nat Commun. 2019 Apr 23; 10(1): 1914.

Chemical Properties

Cas No. 685119-25-9 SDF
Canonical SMILES O=C(NC1=C(Br)SC=C1S(=O)(C2=CC=CC=C2)=O)C3=CC=CC=C3Cl
分子式 C17H11BrClNO3S2 分子量 456.76
溶解度 DMSO : 50 mg/mL 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.1893 mL 10.9467 mL 21.8933 mL
5 mM 0.4379 mL 2.1893 mL 4.3787 mL
10 mM 0.2189 mL 1.0947 mL 2.1893 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

A small molecule promotes cartilage extracellular matrix generation and inhibits osteoarthritis development

Nat Commun 2019 Apr 23;10(1):1914.PMID:31015473DOI:10.1038/s41467-019-09839-x.

Degradation of extracellular matrix (ECM) underlies loss of cartilage tissue in osteoarthritis, a common disease for which no effective disease-modifying therapy currently exists. Here we describe BNTA, a small molecule with ECM modulatory properties. BNTA promotes generation of ECM components in cultured chondrocytes isolated from individuals with osteoarthritis. In human osteoarthritic cartilage explants, BNTA treatment stimulates expression of ECM components while suppressing inflammatory mediators. Intra-articular injection of BNTA delays the disease progression in a trauma-induced rat model of osteoarthritis. Furthermore, we identify superoxide dismutase 3 (SOD3) as a mediator of BNTA activity. BNTA induces SOD3 expression and superoxide anion elimination in osteoarthritic chondrocyte culture, and ectopic SOD3 expression recapitulates the effect of BNTA on ECM biosynthesis. These observations identify SOD3 as a relevant drug target, and BNTA as a potential therapeutic agent in osteoarthritis.

BNTA alleviates inflammatory osteolysis by the SOD mediated anti-oxidation and anti-inflammation effect on inhibiting osteoclastogenesis

Front Pharmacol 2022 Sep 29;13:939929.PMID:36249770DOI:10.3389/fphar.2022.939929.

Abnormal activation and overproliferation of osteoclast in inflammatory bone diseases lead to osteolysis and bone mass loss. Although current pharmacological treatments have made extensive advances, limitations still exist. N-[2-bromo-4-(phenylsulfonyl)-3-thienyl]-2-chlorobenzamide (BNTA) is an artificially synthesized molecule compound that has antioxidant and anti-inflammatory properties. In this study, we presented that BNTA can suppress intracellular ROS levels through increasing ROS scavenging enzymes SOD1 and SOD2, subsequently attenuating the MARK signaling pathway and the transcription of NFATc1, leading to the inhibition of osteoclast formation and osteolytic resorption. Moreover, the results also showed an obvious restrained effect of BNTA on RANKL-stimulated proinflammatory cytokines, which indirectly mediated osteoclastogenesis. In line with the in vitro results, BNTA protected LPS-induced severe bone loss in vivo by enhancing scavenging enzymes, reducing proinflammatory cytokines, and decreasing osteoclast formation. Taken together, all of the results demonstrate that BNTA effectively represses oxidation, regulates inflammatory activity, and inhibits osteolytic bone resorption, and it may be a potential and exploitable drug to prevent inflammatory osteolytic bone diseases.

Fatty acid hydrolysis of acyl marinobactin siderophores by Marinobacter acylases

Biochemistry 2015 Jan 27;54(3):744-52.PMID:25588131DOI:10.1021/bi5013673.

The marine bacteria Marinobacter sp. DS40M6 and Marinobacter nanhaiticus D15-8W produce a suite of acyl peptidic marinobactin siderophores to acquire iron under iron-limiting conditions. During late-log phase growth, the marinobactins are hydrolyzed to form the marinobactin headgroup with release of the corresponding fatty acid tail. The BNTA gene, a homologue of the Pseudomonas aeruginosa pyoverdine acylase gene, pvdQ, was identified from Marinobacter sp. DS40M6. A BNTA knockout mutant of Marinobacter sp. DS40M6 produced the suite of acyl marinobactins A-E, without the usual formation of the marinobactin headgroup. Another marinobactin-producing species, M. nanhaiticus D15-8W, is predicted to have two pvdQ homologues, mhtA and mhtB. MhtA and MhtB have 67% identical amino acid sequences. MhtA catalyzes hydrolysis of the apo-marinobactin siderophores as well as the quorum sensing signaling molecule, dodecanoyl-homoserine lactone. In contrast to hydrolysis of the suite of apo-marinobactins by MhtA, hydrolysis of the iron(III)-bound marinobactins was not observed.

The First Injection: Rates of Urinary Retention in Women With Urgency Incontinence Treated With Intravesical OnabotulinumtoxinA Injection

Female Pelvic Med Reconstr Surg 2021 Jan 1;27(1):e118-e121.PMID:32487882DOI:10.1097/SPV.0000000000000847.

Objective: The aim of the study was to describe the rate of symptomatic and asymptomatic urinary retention and catheterization in women undergoing initial intravesical onabotulinumtoxinA (BNTA) injection for urgency urinary incontinence (UUI). Methods: This retrospective chart review included women receiving initial 100 U of BNTA injection for UUI for 5 years. Straight-catheterized postvoid residuals (PVRs) were performed 2 weeks after the injection. Women without the sensation of incomplete bladder emptying, worsened urgency, inability to void, or suprapubic pain but with PVR of greater than 300 mL were characterized as having asymptomatic retention, whereas women with a PVR of greater than 150 and any of these symptoms were diagnosed with symptomatic retention. Results: One hundred eighty-seven 187 patients received initial BNTA injection. The majority were postmenopausal (89%) and white (82%) with a mean age of 65 years and body mass index of 30 kg/m2. One-third of the cohort underwent baseline urodynamic studies. At 2 weeks after injection, 163 patients (87%) followed up, and 17 (10%) had either asymptomatic or symptomatic retention (2% and 8%, respectively). There were no differences in demographic or pretreatment urodynamic parameters in women with and without retention except that women who had previous anti-stress urinary incontinence procedures were more likely to experience retention (53% vs 18%, P = 0.002) despite similar baseline PVRs. Conclusion: We demonstrated that the rate of retention requiring catheterization after 100 U BNTA may be as high as 10% although only 5% develop PVRs for 300 mL and only 2% have asymptomatic retention for 300 mL.

Synthesis and Stabilization of Blue-Black TiO2 Nanotube Arrays for Electrochemical Oxidant Generation and Wastewater Treatment

Environ Sci Technol 2016 Nov 1;50(21):11888-11894.PMID:27648479DOI:10.1021/acs.est.6b03540.

Efficient, inexpensive, and stable electrode materials are key components of commercially viable electrochemical wastewater treatment system. In this study, blue-black TiO2 nanotube array (BNTA) electrodes are prepared by electrochemical self-doping. The 1-D structure, donor state density, and Fermi energy level position are critical for maintaining the semimetallic functionality of the BNTA. The structural strength of the BNTA is enhanced by surface crack minimization, reinforcement of the BNTA-Ti metal interface, and stabilized by a protective overcoating with nanoparticulate TiO2 (Ti/EBNTA). Ti/EBNTA electrodes are employed as both anodes and cathodes with polarity switching at a set frequency. Oxidants are generated at the anode, while the doping levels are regenerated along with byproduct reduction at the cathode. The estimated maximum electrode lifetime is 16 895 h. Ti/EBNTA has comparable hydroxyl radical production activity (6.6 × 10-14 M) with boron-doped diamond (BDD, 7.4 × 10-14 M) electrodes. The chlorine production rate follows a trend with respective to electrode type of Ti/EBNTA > BDD > IrO2. Ti/EBNTA electrodes operated in a bipolar mode have a minimum energy consumption of 62 kWh/kg COD, reduced foam formation due to less gas bubble production, minimum scale formation, and lower chlorate production levels (6 mM vs 18 mM for BDD) during electrolytic wastewater treatment.